secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2024-07-09T23:59:59+00:00
Accession:  0000950170-24-082307
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio completes SIGNAL-AD Phase 2 enrollment; topline data expected Q4 2024
-----------------------------------------------------------------------------

- Enrolled 121 patients in SIGNAL-AD Phase 2 trial, exceeding original target of ~100.
- Part B randomized 1:1 to bempikibart 200 mg Q2W SC or placebo for 12 weeks.
- Primary endpoint: mean % change from baseline in EASI score at week 14.
- SIGNAL-AA (alopecia areata) enrollment also completed; both topline data due Q4 2024.
- CEO cites patient demand as driver of enrollment surpassing initial target.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000095017024082307/0000950170-24-082307-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000095017024082307/qttb-20240709.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-082307

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer